Literature DB >> 32533361

Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies.

Joseph C Kong1, Oliver Peacock1, Peadar S Waters2, Tim Eglinton3, Satish K Warrier1, Christopher Wakeman3, Frank A Frizelle3, Alexander G Heriot1, Jacob J McCormick1.   

Abstract

PURPOSE: In an era of personalised medicine, there is an overwhelming effort for predicting patients who will benefit from extended radical resections for locally advanced pelvic malignancy. However, there is paucity of data on the effect of comorbidities and postoperative complications on long-term overall survival (OS). The aim of this study was to define predictors of 1-year and 5-year OS.
METHODS: Data were collected from prospective databases at two high-volume institutions specialising in beyond TME surgery for locally advanced and recurrent pelvic malignancies between 1990 and 2015. The primary outcome measures were 1-year and 5-year OS.
RESULTS: A total of 646 consecutive extended radical resections were performed between 1990 and 2015. The majority were female patients (371, 57.4%) and the median age was 63 years (range 19-89 years). One-year OS, primary rectal adenocarcinoma had the best survival while recurrent colon cancer had the worse survival (p = 0.047). The 5-year OS between primary and recurrent cancers were 64.7% and 53%, respectively (p = 0.004). Poor independent prognostic markers for 5-year OS were increasing ASA score, cardiovascular disease, recurrent cancers, ovarian cancers, pulmonary embolus and acute respiratory distress syndrome. A positive survival benefit was demonstrated with preoperative radiotherapy (HR 0.55; 95% CI 0.4-0.75, p < 0.001).
CONCLUSION: Patient comorbidities and specific complications can influence long-term survival following extended radical resections. This study highlights important predictors, enabling clinicians to better inform patients of the potential short- and long-term outcomes in the management of locally advanced and recurrent pelvic malignancy.

Entities:  

Keywords:  Pelvic malignancy; Primary cancer; Radical resection; Recurrent cancer

Mesh:

Year:  2020        PMID: 32533361     DOI: 10.1007/s00423-020-01895-y

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  28 in total

1.  Pelvic exenteration operations: with summary of sixty-six cases surviving more than five years.

Authors:  A BRUNSCHWIG; W DANIEL
Journal:  Ann Surg       Date:  1960-04       Impact factor: 12.969

2.  Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy.

Authors:  A BRUNSCHWIG
Journal:  Cancer       Date:  1948-07       Impact factor: 6.860

3.  Pelvic exenteration, University of Michigan: 100 patients at 5 years.

Authors:  G W Morley; M P Hopkins; S M Lindenauer; J A Roberts
Journal:  Obstet Gynecol       Date:  1989-12       Impact factor: 7.661

4.  Determinants of survival following pelvic exenteration for primary rectal cancer.

Authors:  R W Radwan; H G Jones; N Rawat; M Davies; M D Evans; D A Harris; J Beynon
Journal:  Br J Surg       Date:  2015-06-11       Impact factor: 6.939

5.  Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer.

Authors:  Panagiotis A Georgiou; Paris P Tekkis; Vasilis A Constantinides; Uday Patel; Robert D Goldin; Ara W Darzi; R John Nicholls; Gina Brown
Journal:  Eur J Cancer       Date:  2012-10-01       Impact factor: 9.162

6.  Impact of multimodal therapy in locally recurrent rectal cancer.

Authors:  Y N You; J M Skibber; C-Y Hu; C H Crane; P Das; E S Kopetz; C Eng; B W Feig; M A Rodriguez-Bigas; G J Chang
Journal:  Br J Surg       Date:  2016-03-02       Impact factor: 6.939

7.  Overall survival after pelvic exenteration for gynecologic malignancy.

Authors:  Shannon N Westin; Vijayashri Rallapalli; Bryan Fellman; Diana L Urbauer; Navdeep Pal; Michael M Frumovitz; Lois M Ramondetta; Diane C Bodurka; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2014-07-09       Impact factor: 5.482

8.  Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017.

Authors:  Sandra I Berríos-Torres; Craig A Umscheid; Dale W Bratzler; Brian Leas; Erin C Stone; Rachel R Kelz; Caroline E Reinke; Sherry Morgan; Joseph S Solomkin; John E Mazuski; E Patchen Dellinger; Kamal M F Itani; Elie F Berbari; John Segreti; Javad Parvizi; Joan Blanchard; George Allen; Jan A J W Kluytmans; Rodney Donlan; William P Schecter
Journal:  JAMA Surg       Date:  2017-08-01       Impact factor: 14.766

9.  Cohort study of long-term survival and quality of life following pelvic exenteration.

Authors:  D Steffens; M J Solomon; J M Young; C Koh; R L Venchiarutti; P Lee; K Austin
Journal:  BJS Open       Date:  2018-05-22

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.